COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,886 Articles (22,568 medRxiv, 8,318 bioRxiv)

Most recent first Previous |  Page 851: Articles 8501-8510  | Next

The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK
Hill, V., du Plessis, L., Peacock, T. P. A., Aggarwal, D., Carabelli, A., Colquhoun, R., Ellaby, N., Gallagher, E., Groves, N., Jackson, B., McCrone, J., O'Toole, A. N., Price, A., Sanderson, T., Scher, E., Southgate, J. A., Volz, E., The COVID-19 genomics UK (COG-UK) consortium, , Barclay, W. S., Barrett, J., Chand, M., Connor, T. R., Goodfellow, I. G., Gupta, R. K., Harrison, E., Loman, N., Myers, R., Robertson, D. L., Pybus, O., Rambaut, A.
10.1101/2022.03.08.481609 — Posted: 2022-03-08
Anti-spike antibody response to natural infection with SARS-CoV-2 and its activity against emerging variants
Chen, C.-P., Huang, K.-Y. A., Shih, S.-R., Lin, Y.-C., Cheng, C.-Y., Huang, Y.-C., Lin, T.-Y., Cheng, S.-H.
10.1101/2022.03.07.481737 — Posted: 2022-03-08
Patients at risk of pulmonary fibrosis Post Covid-19: Epidemiology, pulmonary sequelaes and humoral response
Hernandez Porto, M., Delgado, T., Aguirre-Jaime, A., Ramos, M. J., Campos, S., Acosta, O., LLanos, A. B., Lecuona, M.
10.1101/2022.03.04.22271920 — Posted: 2022-03-07
Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study
Bosch, G., Posso, M., Louro, J., Roman, M., Porta, M., Castells, X., Macia, F.
10.1101/2022.03.04.22271911 — Posted: 2022-03-07
GWAS and meta-analysis identifies multiple new genetic mechanisms underlying severe Covid-19.
Pairo-Castineira, E., Rawlik, K., Klaric, L., Law, A., Clohisey Hendry, S., Baillie, J. K.
10.1101/2022.03.07.22271833 — Posted: 2022-03-07
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis
Beckerman, R., Gori, A., Jeyakumar, S., Malin, J. J., Paredes, R., Povoa, P., Smith, N. J., Teixeira-Pinto, A.
10.1101/2022.03.04.22271706 — Posted: 2022-03-07
Competitive fitness of emerging SARS-CoV-2 variants is linked to their Distinctiveness relative to preceding lineages from that region
Niesen, M. J., Murugadoss, K., Venkatakrishnan, A., Lenehan, P. J., Soundararajan, V.
10.1101/2022.03.06.22271974 — Posted: 2022-03-07
Changing dynamics of SARS-CoV2 B.1.617.2 (Delta variant) outbreak in the United Kingdom: Shifting of SARS-CoV2 infections from younger to elderly populations with increasing hospitalizations and mortality among elderly.
Emani, V. R. R., Nakka, A. S., Goswami, K. K., Emani, S. R., Maddula, K. R., Reddy, N. K., Reddy, N. K., Nandanoor, D., Goswami, S., Reddy, R.
10.1101/2022.03.05.22271084 — Posted: 2022-03-07
In silico screening and testing of FDA approved small molecules to block SARS-CoV-2 entry to the host cell by inhibiting Spike protein cleavage
Ozdemir, E. S., Le, H. H., Yildirim, A., Ranganathan, S. V.
10.1101/2022.03.07.483324 — Posted: 2022-03-07
Angiotensin converting enzyme 2 (ACE2): Virus accomplice or host defender
Wang, J., Chang, H., Qiao, Y., Sun, H., Li, X., Yuan, S., Zhang, S., Shan, C.
10.1101/2022.03.06.483197 — Posted: 2022-03-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).